Suicide prevention treatment

PreclinicalSmall molecule

WWeill Medical College of Cornell University

Suicide prevention treatment is one of 32 small molecule programs targeting Suicide. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SuicideActive, not recruiting

SuicidePreclinical

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Suicide

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

6 2

Estrace

Spravato

2 4

Paxil

SSebela Pharmaceuticals Development LLC

Approved

1 5

Lexapro

AbbVie

Phase 3

1 6

Celexa

AbbVie

Phase 3

1 7

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Approved

1 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

2 9

Suboxone

IIndivior Inc.

Phase 3

1 10

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Suicide1 trial

Prevention of Suicide in the Elderly

Completed·WWeill Medical College of Cornell University·N/A·NCT00000367

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Suicide prevention treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Suicide prevention treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Suicide prevention treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWeill Medical College of Cornell University

Suicide prevention treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Suicide1 trial

References

Drug Info

Quick Facts

Related News